Lineage Cell Therapeutics Q3 EPS Lifted by HC Wainwright

Key Points

• HC Wainwright has raised its Q3 2025 earnings estimate for Lineage Cell Therapeutics to (-$0.01) per share, improving from the previous estimate of (-$0.02).
• Five analysts currently rate Lineage Cell Therapeutics' stock with a Buy rating, and it holds an average target price of $4.20.
• Lineage Cell Therapeutics has seen significant institutional interest, with notable increases in stakes from firms like JPMorgan Chase and Renaissance Technologies in the last quarter.

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - HC Wainwright raised their Q3 2025 EPS estimates for Lineage Cell Therapeutics in a report issued on Wednesday, August 13th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.01) for the quarter, up from their prior estimate of ($0.02). HC Wainwright has a "Buy" rating and a $9.00 price target on the stock. The consensus estimate for Lineage Cell Therapeutics' current full-year earnings is ($0.12) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics' Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.18) EPS and FY2027 earnings at ($0.04) EPS.

Separately, D. Boral Capital reiterated a "buy" rating and issued a $2.00 target price on shares of Lineage Cell Therapeutics in a research report on Thursday, August 14th. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Lineage Cell Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $4.25.

Lineage Cell Therapeutics Trading Down 3.6%

Lineage Cell Therapeutics stock traded down $0.0450 during midday trading on Friday, reaching $1.1950. The company's stock had a trading volume of 912,070 shares, compared to its average volume of 1,921,147. Lineage Cell Therapeutics has a 52 week low of $0.3651 and a 52 week high of $1.31. The business has a 50-day moving average price of $1.00 and a 200-day moving average price of $0.69. The stock has a market cap of $272.89 million, a PE ratio of -6.64 and a beta of 1.66.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Hudson Bay Capital Management LP bought a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter worth about $44,000. Brevan Howard Capital Management LP bought a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter worth about $281,000. Raymond James Financial Inc. raised its position in shares of Lineage Cell Therapeutics by 136.2% during the 2nd quarter. Raymond James Financial Inc. now owns 69,380 shares of the company's stock worth $63,000 after buying an additional 40,009 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter worth about $35,000. Finally, WINTON GROUP Ltd bought a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter worth about $69,000. Institutional investors own 62.47% of the company's stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.